XML 56 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Note 2 - Significant Accounting Policies (Details Textual)
€ in Thousands
12 Months Ended
Dec. 31, 2024
EUR (€)
shares
Dec. 31, 2023
EUR (€)
shares
Dec. 31, 2022
shares
Income Tax Expense (Benefit) € 0 € 0  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | shares 33,689 35,119 37,924
Convertible Debt, Indexed Common Shares (in shares) | shares 15,771,230    
Number of Operating Segments 1    
Research and Development Expense € 1,118 € 16,136  
Accounts Payable and Other Accrued Liabilities, Current 575 56,576  
Retained Earnings (Accumulated Deficit) € (321,428) (386,454)  
Previously Reported [Member]      
Research and Development Expense   15,783  
Accounts Payable and Other Accrued Liabilities, Current   55,798  
Retained Earnings (Accumulated Deficit)   € (385,677)  
Minimum [Member]      
Property, Plant and Equipment, Useful Life (Year) 5 years    
Maximum [Member]      
Property, Plant and Equipment, Useful Life (Year) 7 years